Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | The development of novel treatment modalities: regulations and expectations

Saar Gill • 5 Oct 2017
ESH 2017
General

Novel technologies have the potential to allow us to treat more ailments, but often come at the price of new toxicities. Speaking from the International Conference of Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Saar Gill, MD, PhD from the University of Pennsylvania, Philadelphia, PA discusses how stronger regulations and greater transparency between scientists, patients and physicians has impacted these new technologies. Dr Gill also highlights the necessity of controlling side effects and the importance of managing expectations.

More from Saar Gill

16:12
Exploring the potential of CAR-T therapy in CLL
John Gribben et al. • 30 Apr 2022
25:18
Addressing the major challenges to CAR-T therapy in AML
John DiPersio et al. • 30 Apr 2022
14:18
Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
David Maloney et al. • 11 Oct 2019
13:25
CLL and CAR-T
Jordan Gauthier et al. • 11 Oct 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals